Highlights

• All figures in United States dollars. Normalized total cash receipts rose 9% to $47.5 million; Adjusted EBITDA rose 9% to $40.0 million with an 84% margin.

• The $316 million Juvmo (tavapadon) Royalty purchase closed on September 29, 2026, the largest transaction in the trust's history.

• Fiscal 2026 Adjusted EBITDA is now expected to exceed the top of the $157 million to $162 million guided range; quarterly distribution of $0.11 per unit declared.

DRI Healthcare Trust (TSX:DHT.UN) reported its third-quarter results for the period ended in late September in a release issued on Wednesday of last week, pairing higher royalty cash receipts with a raised full-year Earnings outlook. The Toronto-based trust, which also lists United States dollar units under TSX:DHT.U, described the quarter as one defined by the completion of its largest transaction to date, a royalty on a neurology medicine named Juvmo.

A Royalty Owner, Not a Drug Developer

DRI Healthcare describes itself as a pioneer in global pharmaceutical royalty monetization. Founded in the late nineteen-eighties, the organization says it has deployed more than three billion dollars, acquiring royalties on dozens of drugs. The model is straightforward in concept: instead of researching and developing molecules, the trust purchases the right to a share of future sales of approved or near-approved medicines, then collects payments as those products reach patients. Cash arrives quarterly, usually on a one-quarter lag, and the trust does not carry the clinical or Manufacturing burden of the products it follows.

That structure explains why the company reports measures such as normalized total cash receipts and Adjusted EBITDA Margin rather than product revenue. Management reported an Adjusted EBITDA margin in the mid-eighty percent range for the quarter, a level that reflects how little operating cost sits between a royalty payment and the trust's income statement. Those measures are non-standard under IFRS, and the release includes reconciliations, so careful readers will compare them with the audited statements in the management discussion and analysis.

What the Quarter Delivered

Normalized total cash receipts rose roughly nine percent from the prior-year quarter, and Adjusted EBITDA increased by a similar proportion. Adjusted cash earnings per unit were slightly lower than a year earlier, which illustrates a common tension for royalty owners: when new Assets are funded with borrowed money and cash on hand, earnings per unit can lag until the new streams begin paying. Total income was lower than the comparable quarter, yet comprehensive earnings swung to a healthy gain from a large loss a year earlier, helped by foreign-exchange and valuation movements.

Over the first nine months of the year, total income, cash receipts and Adjusted EBITDA all exceeded the same period last year, and the Adjusted EBITDA margin widened considerably. A net gain on the disposition of royalty assets contributed, offset in part by a loss on Debt refinancing. A non-cash Impairment was also recorded against the royalty on Zejula, a reminder that royalty values can be marked down when generic competition or shifting prescribing patterns erode expected sales.

Juvmo, Ekterly and Capital Recycling

The Juvmo purchase closed on the final days of September, funded with cash on hand and borrowings under the Credit facility. The Acquisition entitles the trust to tiered royalties on annual United States net sales of tavapadon, certain sales-based milestones and four annual fixed payments of a little over twenty-three million dollars each, with aggregate receipts capped at roughly four hundred and thirty-seven million dollars. The first royalty receipt is expected only in the quarter after the first United States commercial sale, so the contribution to cash receipts is a future event rather than a present one.

The financing came after an earlier asset left the portfolio. A Put Option on the Ekterly royalty was exercised in July after the drug's developer was acquired, and the trust received a net repurchase price of about one hundred and seventy-eight million dollars in early August. Management pointed to the sequence as evidence that proceeds can be redeployed quickly into new assets. Separately, the approval of Lumvoa for thyroid eye disease triggered a milestone payment owed by the trust, while unmet clinical milestones on a related program lowered its maximum remaining obligation.

Outlook and Distribution Policy

Management said the trust is tracking above the upper end of its previously communicated aspirational targets for the years through the end of the decade, and expects full-year Adjusted EBITDA to exceed the top of the earlier guided range. Guidance of that kind carries forward-looking risk, and the release lists generic competition, royalty duration, currency and interest-rate movements and financing conditions among the factors that could cause actual outcomes to differ.

On distributions, the trust paid a quarterly amount of eleven cents per unit in October and declared the same amount for the fourth quarter, payable in January to unitholders of record at the end of December. Readers following Healthcare Stocks will note that royalty vehicles occupy a distinct corner of the sector, offering exposure to drug sales without direct research-and-development spending, though income still depends on third-party commercial execution.

Balance Sheet and Portfolio Texture

At quarter end the trust reported modest cash against long-term debt of just over five hundred and seventy million dollars, spread across a credit facility, preferred securities, convertible debentures and senior notes. After a large acquisition funded partly by borrowing, Leverage and refinancing capacity become central watch items, particularly while the Juvmo stream has yet to produce its first quarterly receipt. Interest-rate direction set by the Bank of Canada and the Federal Reserve influences both borrowing costs and the way markets value long-duration income streams.

The royalty portfolio spans dozens of streams across oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders and immunology. The largest contributors to third-quarter cash receipts included Omidria, the two Orserdu royalty streams, Xolair and Spinraza. Diversification across therapeutic areas and counterparties reduces dependence on any single product, but concentration in the top few streams remains visible in the quarterly detail.

Risks and What Comes Next

Several uncertainties deserve attention. Royalty streams are finite, and Patent expiry or biosimilar entry can reduce receipts abruptly. Regulatory decisions on partner products, pricing policy in the United States, and exchange-rate movements between the Canadian dollar and the United States dollar all feed into reported results, since the trust reports primarily in United States dollars while units also trade in Canadian dollars. Share repurchases under the normal course issuer bid were modest in the quarter, with roughly one hundred and forty-six thousand units repurchased, which signals a balance between buybacks, distributions and new acquisitions.

Investors tracking the [S&P/TSX Composite Index] will find that healthcare carries a small weight relative to financials and energy, so a royalty issuer like this one tends to be followed for its idiosyncratic cash-flow profile rather than for sector beta. Upcoming milestones to monitor include the regulatory path and commercial launch timing for Juvmo, any further royalty acquisitions funded from the credit facility, the evolution of the Zejula royalty, and the fourth-quarter results that will show whether full-year Adjusted EBITDA lands where management now expects.